Schizophrenia and liver dysfunction caused by portacaval shunting

Current Psychiatry Reviews

Volumn 3, Issue 3, 2007, Pages 205-212

  Krøll, Jens ^a,b  

^a BLEKINGE HOSPITAL   (Sweden)

^b NONE   (Denmark)

Author keywords

Cerebral decortications; Neurotoxins; Neurotransmitters; Portacaval shunt; Schizophrenia; Stress response

Indexed keywords

4 AMINOBUTYRIC ACID; ALBUMIN; BILIRUBIN; DOPAMINE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTAMINE; HYDROCORTISONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELATONIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SEROTONIN;

BILIRUBIN METABOLISM; BLOOD BRAIN BARRIER; BRAIN ATROPHY; CATATONIC SCHIZOPHRENIA; COGNITIVE DEFECT; CYTOTOXICITY; DOPPLER ECHOGRAPHY; GLUCOSE METABOLISM; HEBEPHRENIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMAGE ANALYSIS; IMMUNE RESPONSE; LIPID PEROXIDATION; LIVER DYSFUNCTION; MEDLINE; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARANOID SCHIZOPHRENIA; PATHOGENESIS; PORTAL VEIN; PORTOCAVAL SHUNT; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; SCHIZOPHRENIA; SHARED PSYCHOTIC DISORDER; STRESS;

EID: 34548299108     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340007781369711     Document Type: Review

References (115)

1. Buscaino GA. The amino-hepato-entero-toxic theory of schizophrenia: an historical evaluation. In The biological basis of schizophrenia. Hemmings G, Hemmings WA. Lancaster: MTP Press; 1978, pp 45-54.
2. Kroll J. Schizophrenia and liver dysfunction. Med Hypotheses 2001; 56(5): 634-6.
3. DiMartini A, Twillman R. Organ transplantation and paranoid schizophrenia. Psychosomatics 1994; 35: 159-61.
4. Watanabe A. Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment. J Gastroenterol Hepatol 2000; 15 (9): 969-79.
5. Wakefield AJ, Puleston JM, Montgomery SM, Anthony A, O'Leary JJ, Murch SH. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002; 16 (4): 663-74.
6. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J Autism Dev Disord 2004; 34 (6): 615-23.
7. Ricós C, Doménech MV, Perich C. Analytical quality specifications for common reference intervals. Clin Chem Lab Med 2004; 42 (7): 858-62.
8. Jover R, Madaria E, Felipo V, Rodrigo R, Candela A, Compañ A. Animal models in the study of episodic hepatic encephalopathy in cirrhosis. Metab Brain Dis 2005; 20 (4): 399-408.
9. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F] fluorodopa study. Arch Gen Psychiatry 2004; 61(2): 134-42.
10. Nieminen-von Wendt TS, Metsähonkala L, Kulomäki TA, et al. Increased presynaptic dopamine function in Asperger syndrome. Neuroreport 2004; 15(5): 757-60.
11. Bergeron M, Swain MS, Reader TA, Butterworth RF. Regional alterations of dopamine and its metabolites in rat brain following portacaval anastomosis. Neurochem Res 1995; 20: 79-86.
12. Baumeister AA, Francis JL. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 2002; 11(3): 265-77.
13. Kurup RK, Kurup PA. Schizoid neurochemical pathology-induced membrane Na(+)-K+ ATPase inhibition in relation to neurological disorders. Int J Neurosci 2003; 113 (12): 1705-17.
14. Muck-Seler D, Pivac N, Mustapic M, Crncevic Z, Jakovljevic M, Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004; 127 (3): 217-26.
15. Lozeva V, Montgomery JA, Tuomisto L, et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004; 40 (5): 742-8.
16. East SZ, Burnet PW, Kerwin RW, Harrison PJ. An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr Res 2002; 57 (1): 15-26.
17. Apelqvist G, Bergqvist PB, Larsson B, Bugge M, Bengtsson F. Regional brain serotonin receptor changes in portacaval shunted rats. Acta Physiol Scand 1998; 162 (4): 509-16.
18. Reinhard JF. Pharmacological manipulation of brain kynurenine metabolism. Ann N Y Acad Sci 2004; 1035: 335-49.
19. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 2005; 80 (2-3): 315-22.
20. Saran T, Hilgier W, Urbanska EM, Turski WA, Albrecht J. Kynurenic acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide-induced hepatic encephalopathy. J Neurosci Res 2004; 75 (3): 436-40.
21. Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India 2000; 48 (3): 231-8.
22. Holt DE, Washabau RJ, Djali S, et al. Cerebrospinal fluid glutamine, tryptophan, and tryptophan metabolite concentrations in dogs with portosystemic shunts. Am J Vet Res 2002; 63 (8): 1167-71.
23. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9(11): 984-97 979.
24. van Elst LT, Valerius G, Buchert M, et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58 (9): 724-30.
25. Ibrahim HM, Hogg AJ, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000; 157 (11): 1811-23.
26. Harrison PJ, Law AJ, Eastwood SL. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann N Y Acad Sci 2003; 1003: 94-101.
27. Chan H, Butterworth RF. Cell-selective effects of ammonia on glutamate transporter and receptor function in the mammalian brain. Neurochem Int 2003; 43 (4-5): 525-32.
28. Blum BP, Mann JJ. The GABAergic system in schizophrenia. Int J Neuropsychopharmacol 2002; 5 (2): 159-79.
29. Kalkman HO, Loetscher E. GAD (67): The link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. J Neural Transm 2003; 110 (7): 803-12.
30. Fatemi SH, Hossein Fatemi S, Stary JM, Earle JA, Araghi-Niknam M, Eagart E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 2005; 72(2-3): 109-22.
31. Guidotti A, Auta J, Davis JM, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 2005; 180(2): 191-205.
32. Imai K, Harada S, Kawanishi Y, Tachikawa H, Okubo T, Asada T. Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Am J Med Genet 2002; 26(2): 393-6.
33. Zeneroli ML, Baraldi M, Ventura E, et al. Alterations of GABA-A and dopamine D-2 brain receptors in dogs with portal-systemic encephalopathy. Life Sciences 1991; 48(1): 37-50.
34. Sonnewald U, Therrien G, Butterworth RF. Portacaval anastomosis results in altered neuron - astrocytic metabolic trafficking of amino acids: evidence from 13C-NMR studies. J Neurochem 1996; 67(4): 1711-7.
35. Oja SS, Saransaari P, Wysmyk U, Albrecht J. Loss of GABAB binding sites in the cerebral cortex of rats with acute hepatic encephalopathy. Brain Res 1993; 629(2): 355-7.
36. Ohrmann P, Siegmund A, Suslow T, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005; 73(2-3): 153-7.
37. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005; 5(1): 6.
38. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160(12): 2231-3.
39. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res 2005; 75(1): 27-34.
40. Hass HG, Nägele T, Seeger U, Hösl F, Gregor M, Kaiser S. Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS). Z.Gastroenterol 2005; 43(4): 373-8.
41. Romero-Gómez M. Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2005; 20(4): 319-25.
42. Suárez I, Bodega G, Fernández B. Glutamine synthetase in brain: effect of ammonia. Neurochem Int 2002; 41(2-3): 123-42.
43. Kurumaji A, Watanabe A, Kumashiro S, Semba J, Toru M. A postmortem study of glycine and its potential precursors in chronic schizophrenics. Neurochem Int 1996; 29(3): 239-45.
44. Zwingmann C, Desjardins P, Hazell A, Chatauret N, Michalak A, Butterworth RF. Reduced expression of astrocytic glycine transporter (Glyt-1) in acute liver failure. Metab Brain Dis 2002; 17(4): 263-73.
45. Ito C. The role of the central histaminergic system on schizophrenia. Drug News Perspect 2004; 17(6): 383-7.
46. Lozeva V, Attila M, Anttila E, Laitinen K, Hippeläinen M, Tuomisto L. Brain histamine H3 receptors in rats with portacaval anastomosis: in vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol 1998; 358(5): 574-81.
47. Schmauss C, Emrich HM. Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry 1985; 20(11): 1211-31.
48. Yurdaydin C, Karavelioglu D, Onaran O, Celik T, Yasa MH, Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998; 29(5): 796-801.
49. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160(2): 284-9.
50. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005; 20(4): 183-98.
51. Satoh M, Yokoya S, Hachiya Y et al. Two hyperandrogenic adolescent girls with congenital portosystemic shunt. Eur J Pediatr 2001; 160(5): 307-11.
52. Williamson MP, Behme MT, Dupré J, Grant DR, Guan J, Zhong R. Rats with portal-caval vein transposition show hyperinsulinemia and insulin resistance. Metabolism 1996; 45(1): 120-5.
53. Huang TL. Decreased serum albumin levels in Taiwanese patients with schizophrenia. Psychiatry Clin Neurosci 2002; 56(6): 627-30.
54. Yang SS, Lai YC, Chiang TR, Chen DF, Chen DS. Role of zinc in subclinical hepatic encephalopathy: comparison with somatosensory-evoked potentials. J Gastroenterol Hepatol 2004; 19(4): 375-9.
55. Niles JD, Williams JM, Cripps PJ. Hemostatic profiles in 39 dogs with congenital portosystemic shunts. Vet Surg 2001; 30(1): 97-104.
56. Rigato I, Ostrow JD, Tiribelli C. Bilirubin and the risk of common non-hepatic diseases. Trends Mol Med 2005; 11(6): 277-83.
57. Lopes Filho Gde J, Haddad CM. Late clinical, biochemical, endoscopic and electroencephalographic evaluation of patients with schistosomal portal hypertension treated with distal splenorenal shunt. Int Surg 1998; 83(1): 42-7.
58. Viganò D, Lissoni P, Rovelli F, et al. A study of light /dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuroendocrinol Lett 2001; 22(2): 137-41.
59. Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuroendocrinol Lett 2003; 24(3-4): 181-4.
60. Steindl PE, Finn B, Bendok B, Rothke S, Zee PC, Blei AT. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Am Intern Med 1995; 123(4): 274-7.
61. Chong-Thim W, Wing-Foo T, Nilmani S. Serum immunoglobulin levels in Chinese male schizophrenics. Schizophr Res 1993; 10: 61-6.
62. Machraoui A, Rasche B, Oellig WP, Thiel H. Protease inhibitors, serum endotoxin and serum immunoglobulins following portacaval end-to-side anastomosis in animal experiments. Z Gastroenterol 1985; 23(3): 130-8.
63. Hart DJ, Heath RG, Sautter Jr FJ, et al. Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Biol Psychiatry 1999; 45: 704-14.
64. Dickerson FB, Boronow JJ, Stallings C, Origoni AE, Ruslanova I, Yolken RH. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 2003; 60(5): 466-72.
65. Galbraith RM, Eddleston AL, Williams R, et al. Enhanced antibody responses in active chronic hepatitis: relation to HLA-B8 and HLA-B12 and porto-systemic shunting. Lancet 1976; 1(7966): 930-4.
66. Kroll J. E. coli antibodies in schizophrenia. Psychol Med 1986; 16: 209-11.
67. Prytz H, Bjorneboe M, Johansen TS, Orskov F. The influence of portosystemic shunt operation on immunoglobulins and Escherichia coli antibodies in patients with cirrhosis of the liver. Acta Med Scand 1974; 196: 109-12.
68. Gaughran F. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. Int Rev Neurobiol 2002; 52: 275-302.
69. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol 2005; 83(1): 9-17.
70. Vidali M, Stewart SF, Rolla R, et al. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003; 37(2): 410-9.
71. Hosoda H, Okawa-Takatsuji M, Tanaka A, et al. Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions. Clin Chim Acta 2004; 342(1-2): 71-81.
72. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull 2003; 29(4): 671-92.
73. Sterczer A, Meyer HP, Van Sluijs FJ, Rothuizen J. Fast resolution of hypercortisolism in dogs with portosystemic encephalopathy after surgical shunt closure. Res Vet Sci 1999; 66: 63-7.
74. Akyol O, Herken H, Uz E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(3): 995-1005.
75. Stewart CA, Cerhan J. Hepatic encephalopathy: a dynamic or static condition. Metab Brain Dis 2005; 20(3): 193-204.
76. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 2002; 8(3): 177-200.
77. Bernstein HG, Krell D. Braunewell KH, et al. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol 2001; 30(8): 661-70.
78. Rao VL. Nitric oxide in hepatic encephalopathy and hyperammonemia. Neurochem Int 2002; 41(2-3): 161-70.
79. Suárez I, Bodega G, Rubio M, Felipo V, Fernández B. Neuronal and inducible nitric oxide synthase expression in the rat cerebellum following portacaval anastomosis. Brain Res 2005; 1047(2): 205-13.
80. Reddy R, Keshavan MS. Phosphorus magnetic resonance spectroscopy: its utility in examining the membrane hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003; 69(6): 401-5.
81. Clemmesen JO, Høy CE, Jeppesen PB, Ott P. Plasma phospholipid fatty acid pattern in severe liver disease. J Hepatol 2000; 32(3): 481-7.
82. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002; 58(1): 1-10.
83. Murphy MG, Crocker JF, Her H. Abnormalities in hepatic fatty-acid metabolism in a surfactant/influenza B virus mouse model for acute encephalopathy. Biochim Biophys Acta 1996; 1315(3): 208-16.
84. Phillips M, Sabas M, Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. J Clin Pathol 1993; 46(9): 861-4.
85. Moscarella S, Caramelli L, Mannaioni PF, Gentilini P. Effect of alcoholic cirrhosis on ethane and pentane levels in breath. Boll Soc Int Biol Sper 1984, 60: 529-33.
86. Do KQ, Trabesinger AH, Kirsten-Kruger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000; 12(10): 3721-8.
87. Bandara P, George J, McCaughan G, et al. Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver Int 2005; 25(3): 518-26.
88. Benjamin LE, Steele RD. Effect of portacaval shunt on sulfur amino acid metabolism in rats. Am J Physiol 1981; 241(6): G503-8.
89. Schwarz MJ, Riedel M, Gruber R, Muller N, Ackenheil M. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1998; 248: 282-8.
90. Westergaard E. The blood-brain barrier to horseradish peroxidase under normal and experimental conditions. Acta. Neuropathol (Berl) 1977; 39: 181-7.
91. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 2004; 56(4): 255-60.
92. Warbritton JD, Geyer MA, Jeppsson B, Fischer JE. Decreased startle reactivity in the end-to-side portacaval shunted rat. Pharmacol Biochem Behav 1980; 12(5): 739-42.
93. Butler PD, Zemon V, Schechter I, et al. Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch Gen Psychiatry 2005; 62(5): 495-504.
94. Foxe JJ, Doniger GM, Javitt DC. Early visual processing deficits in schizophrenia: impaired P1 generation revealed by high-density electrical mapping. Neuroreport 2001; 12(17): 3815-20.
95. Zamir D, Storch S, Kovach I, Storch R, Zamir C. Early detection of hepatic encephalopathy by recording visual evoked potential (VEP). Rocz Akad Med Bialymst 2002; 47: 186-93.
96. Eastwood SL. The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame? Int Rev Neurobiol 2004; 59: 47-72.
97. Chepkova AN, Sergeeva OA, Haas HL. Taurine rescues hippocampal long-term potentiation from ammonia-induced impairment. Neurobiol Dis 2006; 23(3): 512-21.
98. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005; 133(2): 453-61.
99. Suárez I, Bodega G, Rubio M, Fernández B. Down-regulation of astroglial proteins in the rat cerebellum after portacaval anastomosis. Neuropathol Appl Neurobiol 2005; 31(2): 163-9.
100. Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003; 21(3-4): 97-108.
101. Rothermundt M, Ponath G, Arolt V. S100B in schizophrenic psychosis. Int Rev Neurobiol 2004; 59: 445-70.
102. Schmitt A, Bertsch T, Henning U, et al. Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 2005; 80(2-3): 305-13.
103. Wiltfang J, Nolte W, Otto M, et al. Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metab Brain Dis 1999; 14(4): 239-51.
104. Davatzikos C, Shen D, Gur RC, et al. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Arch Gen Psychiatry 2005; 62(11): 1218-27.
105. Molina V, Sanz J, Sarramea F, Benito C, Palomo T. Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity. J Psychiatr Res 2005; 39(2): 117-27.
106. Gupta RK, Dhiman RK. Magnetic resonance imaging and spectroscopy in hepatic encephalopathy. Indian J Gastroenterol 2003; 22 Suppl 2: S45-9.
107. Halliday GM. A review of the neuropathology of schizophrenia. Clin Exp Pharmacol Physiol 2001; 28(1-2): 64-65.
108. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005; 57(3): 252-60.
109. Uchino T, Matsuda I, Endo F. The long-term prognosis of congenital portosystemic venous shunt. J Pediatr 1999; 135(2 PT 1): 254-6.
110. Smythies JR. Biochemistry and the schizophrenias. South Med J 1979; 72: 1272-6.
111. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005; 5(3): 149-60.
112. van Straten G, Leegwater PA, de Vries M, van den Brom WE, Rothuizen J. Inherited congenital extrahepatic portosystemic shunts in Cairn terriers. J Vet Intern Med 2005; 19(3): 321-4.
113. Gallego C, Velasco M, Marcuello P, Tejedor D, De Campo L, Friera A. Congenital and acquired anomalies of the portal venous system. Radiographics 2002; 22(1): 141-59.
114. Krøll J. Shunts in unexplained psychotic reactions and encephalopathy. Lancet 2002; 359(9319): 1776.
115. Howard ER. Encephalopathy without cirrhosis: hunt the shunt. Gut 1999; 45(3): 329-30.